Stocklytics Platform
Asset logo for symbol CADL
Candel Therapeutics
CADL56
$6.70arrow_drop_up2.91%$0.19
Penny Stock
Asset logo for symbol CADL
CADL56

$6.70

arrow_drop_up2.91%

Performance History

Chart placeholder
Key Stats
Open$6.44
Prev. Close$6.55
EPS-1.29
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$194.90M
PE Ratio-
LOWHIGH
Day Range6.22
6.97
52 Week Range0.66
14.30
Ratios
Revenue-
EBITDA Margin %-
EPS-1.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Candel Therapeutics (CADL)

Candel Therapeutics, Inc. (CADL) is a leading biotechnology company focused on advancing the field of immuno-oncology. With a mission to develop transformative therapies for cancer patients, Candel leverages its deep understanding of the immune system to design and develop innovative treatments. The company's stock price history reflects the growing interest and recognition of its potential in the market.
As of the latest quote, CADL stock is trading at $45.25 per share. This represents a significant increase from its initial public offering price and demonstrates the confidence investors have in Candel Therapeutics. The company has been making headlines lately with its groundbreaking research and development efforts, driving positive stock news and attracting attention from investors and analysts alike.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
Headquarters
Needham
Employees
76
Exchange
NASDAQ
add Candel Therapeutics to watchlist

Keep an eye on Candel Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Candel Therapeutics's (CADL) price per share?
The current price per share for Candel Therapeutics (CADL) is $6.7. The stock has seen a price change of $0.19 recently, indicating a 2.92% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Candel Therapeutics (CADL)?
For Candel Therapeutics (CADL), the 52-week high is $14.3, which is 113.43% from the current price. The 52-week low is $0.66, the current price is 915.15% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Candel Therapeutics (CADL) a growth stock?
Candel Therapeutics (CADL) has shown an average price growth of 0.41% over the past three years. It has received a score of 96 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Candel Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Candel Therapeutics (CADL) stock price performance year to date (YTD)?
As of the latest data, Candel Therapeutics (CADL) has a year-to-date price change of 362.07%. Over the past month, the stock has experienced a price change of 18.58%. Over the last three months, the change has been 4.2%. Over the past six months, the figure is 431.75%.
help
Is Candel Therapeutics (CADL) a profitable company?
Candel Therapeutics (CADL) has a net income of -$37.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$38.39M. Furthermore, the EBITDA is -$35.68M.
help
What is the market capitalization of Candel Therapeutics (CADL)?
Candel Therapeutics (CADL) has a market capitalization of $193.71M. The average daily trading volume is 386.54K, indicating the stock's liquidity and investor engagement.

News

Candel Therapeutics executive sells over $63k in company stock - Investing.com
CANDEL THERAPEUTICS
INSIDER TRANSACTION
STOCK SALE
TAX WITHHOLDING
7/19/2024

Candel Therapeutics executive sells over $63k in company stock - Investing.com

Candel Therapeutics to Join Russell 3000® Index
HEALTH
MANAGEMENT STATEMENTS
6/11/2024

Candel Therapeutics to Join Russell 3000® Index

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
5/28/2024

Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why

Candel (CADL) Reports Upbeat Data From Lung Cancer Study
5/24/2024

Candel (CADL) Reports Upbeat Data From Lung Cancer Study

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
CLINICAL STUDY
5/23/2024

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
CALENDAR OF EVENTS
5/20/2024

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level